Abstract
e15042Background: Most CAR T cell therapy relies on autologous cells with potential limitation in quality of the cells. Cells derived from an allogeneic healthy donor may be more consistent in qual...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
